Published in Stat Med on October 15, 2014
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol (2016) 1.29
Selection Bias Due to Loss to Follow Up in Cohort Studies. Epidemiology (2016) 1.04
Greenness and Birth Outcomes in a Range of Pennsylvania Communities. Int J Environ Res Public Health (2016) 0.89
The impact of adherence to inhaled drugs on 5-year survival in COPD patients: a time dependent approach. Pharmacoepidemiol Drug Saf (2016) 0.77
An Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal Effects. Am J Epidemiol (2016) 0.76
Propensity score and doubly robust methods for estimating the effect of treatment on censored cost. Stat Med (2015) 0.75
Causal inference as an emerging statistical approach in neurology: an example for epilepsy in the elderly. Clin Epidemiol (2016) 0.75
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiol Drug Saf (2017) 0.75
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (2000) 15.40
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med (1990) 7.00
Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods (2004) 5.96
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Super learner. Stat Appl Genet Mol Biol (2007) 5.73
Improving propensity score weighting using machine learning. Stat Med (2010) 4.22
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84
Collaborative double robust targeted maximum likelihood estimation. Int J Biostat (2010) 2.30
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin (2007) 1.83
An application of collaborative targeted maximum likelihood estimation in causal inference and genomics. Int J Biostat (2010) 1.48
Model feedback in Bayesian propensity score estimation. Biometrics (2013) 1.23
Super learning to hedge against incorrect inference from arbitrary parametric assumptions in marginal structural modeling. J Clin Epidemiol (2013) 0.84
Constructing inverse probability weights for marginal structural models. Am J Epidemiol (2008) 12.39
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
Fallibility in estimating direct effects. Int J Epidemiol (2002) 8.34
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed (2004) 5.11
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA (2007) 4.40
The birth weight "paradox" uncovered? Am J Epidemiol (2006) 4.38
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Epidemiology, data sharing, and the challenge of scientific replication. Epidemiology (2009) 3.49
Gout and risk of Parkinson disease: a prospective study. Neurology (2007) 3.09
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. Stat Med (2004) 2.87
Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology (2008) 2.60
Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology (2008) 2.51
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50
Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol (2009) 2.48
Commentary: A structural approach to Berkson's fallacy and a guide to a history of opinions about it. Int J Epidemiol (2014) 2.23
Commentary: how to report instrumental variable analyses (suggestions welcome). Epidemiology (2013) 2.22
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference. Am J Epidemiol (2017) 2.05
Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr (2012) 2.03
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One (2013) 2.03
Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol (2007) 2.00
We are number one but nobody cares-that's good. Epidemiology (2012) 1.97
Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiol Drug Saf (2011) 1.85
Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol (2012) 1.76
Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci (2011) 1.73
Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. AIDS (2012) 1.71
Causal inference from longitudinal studies with baseline randomization. Int J Biostat (2008) 1.69
Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. Epidemiology (2010) 1.64
The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med (2012) 1.63
Randomized trials analyzed as observational studies. Ann Intern Med (2013) 1.60
Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis (2008) 1.60
HIV testing and counselling for migrant populations living in high-income countries: a systematic review. Eur J Public Health (2012) 1.60
Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol (2009) 1.59
Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology (2003) 1.57
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int (2011) 1.56
Impact factor: a call to reason. Epidemiology (2009) 1.54
Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res (2011) 1.49
Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol (2002) 1.46
Antibiotic use and risk of multiple sclerosis. Am J Epidemiol (2006) 1.45
Weight loss in Parkinson's disease. Ann Neurol (2003) 1.43
Weight Loss and Coronary Heart Disease: Sensitivity Analysis for Unmeasured Confounding by Undiagnosed Disease. Epidemiology (2016) 1.39
Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. Epidemiology (2017) 1.38
Causal inference in public health. Annu Rev Public Health (2013) 1.38
Prednisone, lupus activity, and permanent organ damage. J Rheumatol (2009) 1.38
Early versus deferred antiretroviral therapy for HIV. N Engl J Med (2009) 1.35
From causal diagrams to birth weight-specific curves of infant mortality. Eur J Epidemiol (2008) 1.30
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol (2016) 1.29
Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol (2005) 1.27
Invited commentary: composite outcomes as an attempt to escape from selection bias and related paradoxes. Am J Epidemiol (2013) 1.27
Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses (2006) 1.26
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis (2012) 1.25
Hypothetical midlife interventions in women and risk of type 2 diabetes. Epidemiology (2013) 1.23
Body mass index, diabetes, and mortality in French women: explaining away a "paradox". Epidemiology (2014) 1.22
Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry (2010) 1.22
Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol (2003) 1.19
Effect modification by time-varying covariates. Am J Epidemiol (2007) 1.16
Case-only gene-environment interaction studies: when does association imply mechanistic interaction? Genet Epidemiol (2010) 1.15
Relation between three classes of structural models for the effect of a time-varying exposure on survival. Lifetime Data Anal (2009) 1.14
The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis (2006) 1.14
Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care (2012) 1.12
Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS (2006) 1.12
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS (2012) 1.11
Pregnancy outcomes, site of delivery, and community schisms in regions affected by the armed conflict in Chiapas, Mexico. Soc Sci Med (2005) 1.11
Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Mov Disord (2006) 1.11
Obesity and the risk of Parkinson's disease. Am J Epidemiol (2004) 1.09
Counterpoint: Epidemiology to Guide Decision-Making: Moving Away From Practice-Free Research. Am J Epidemiol (2015) 1.08
Matched designs and causal diagrams. Int J Epidemiol (2013) 1.08
Changes in fish consumption in midlife and the risk of coronary heart disease in men and women. Am J Epidemiol (2013) 1.08
Selecting on treatment: a pervasive form of bias in instrumental variable analyses. Am J Epidemiol (2015) 1.07
Smoking, snuff dipping and the risk of amyotrophic lateral sclerosis--a prospective cohort study. Neuroepidemiology (2006) 1.06
HIV Infection in Migrant Populations in the European Union and European Economic Area in 2007-2012: An Epidemic on the Move. J Acquir Immune Defic Syndr (2015) 1.05
Detection of pulmonary tuberculosis in Chiapas, Mexico. Ann Epidemiol (2002) 1.02
Perinatal factors and adult-onset lupus. Arthritis Rheum (2008) 1.01
Invited commentary: Agent-based models for causal inference—reweighting data and theory in epidemiology. Am J Epidemiol (2014) 1.00
Incidence of adult-onset asthma after hypothetical interventions on body mass index and physical activity: an application of the parametric g-formula. Am J Epidemiol (2013) 1.00
From counterfactuals to sufficient component causes and vice versa. Eur J Epidemiol (2006) 1.00
Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol (2003) 0.98
Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. Neurology (2006) 0.97
Folate intake and risk of Parkinson's disease. Am J Epidemiol (2004) 0.95
β-Blocker use for patients with or at risk for coronary artery disease. JAMA (2013) 0.93
Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study. BMC Neurol (2010) 0.93
Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants. Clin Infect Dis (2013) 0.92
Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One (2013) 0.91
Beyond exchangeability: the other conditions for causal inference in medical research. Stat Methods Med Res (2012) 0.90
Think globally, act globally: An epidemiologist's perspective on instrumental variable estimation. Stat Sci (2014) 0.90
HIV testing policies for migrants and ethnic minorities in EU/EFTA Member States. Eur J Public Health (2013) 0.89
Armed conflict and poverty in Central America: the convergence of epidemiology and human rights advocacy. Epidemiology (2007) 0.89
Results on differential and dependent measurement error of the exposure and the outcome using signed directed acyclic graphs. Am J Epidemiol (2012) 0.89
A structural approach to the familial coaggregation of disorders. Epidemiology (2008) 0.88
Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients. Med Care (2014) 0.87
The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration: reply to Llibre and Podzamczer and additional results. AIDS (2013) 0.87
Educational level and HIV disease progression before and after the introduction of HAART: a cohort study in 989 HIV seroconverters in Spain. Sex Transm Infect (2011) 0.87
Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. Curr HIV Res (2009) 0.86